Prognostic value of PSA nadir ≤4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 65, Issue 1, 2006, Pages 73-77

  Nickers, Philippe ^a   Albert, Adelin ^a   Waltregny, David ^a   Deneufbourg, Jean Marie ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Kinetics; Nadir; Prostate; PSA; Radiotherapy

Indexed keywords

DOSIMETRY; MEDICAL APPLICATIONS; PATIENT MONITORING; RADIOTHERAPY; TUMORS; UROLOGY;

NADIR; PROSTATE; PROSTATE-SPECIFIC ANTIGEN (PSA) KINETICS;

ANTIGENS;

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANTIGEN DETECTION; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UROLOGY;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REFERENCE VALUES;

EID: 33645964283     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.11.026     Document Type: Article

References (24)

1. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 277 (1997) 1445-1451
2. Crook J.M., Bahadur Y.A., Bociek R.G., et al. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79 (1997) 328-336
3. Ben-Josef E.A., Shamsa F.A., Forman J.D., et al. Predicting the outcome of radiotherapy for prostate carcinoma. A model-building strategy. Cancer 82 (1998) 1334-1342
4. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
5. Critz F.A., Levinson A.K., Williams W.H., et al. Prostate-specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol 161 (1999) 1199-1203
6. Preston D.M., Bauer J.J., Connelly R.R., et al. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer. Walter Reed Army Medical Center experience, 1988-1995. Urology 53 (1999) 131-138
7. 125Iodine implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 43 (1999) 565-570
8. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high dose rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 316-327
9. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8 months neoadjuvant hormonal therapy before radical prostatectomy. Biochemical and pathological effects. J Urol 166 (2001) 500-597
10. Merrick G.S., Butler W.M., Wallner K.E., et al. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 3 (2004) 141-146
11. Roach M., Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy. A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
12. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
13. Hanks G.E., Pajak T.F., Grignon D., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
14. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high dose rate (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055
15. 192Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma. Radiother Oncol 55 (2000) 41-47
16. Sobin L.H., and Wittekind C.H. TNM classification of malignant tumors (2002), Wiley-Liss, New York
17. Dale R.G. The use of small fraction numbers in high dose-rate gynaecological afterloading. Some radiobiological considerations. Br J Radiol 63 (1990) 290-294
18. Wang J.Z., Li A., Yu C.X., et al. The low α/β ratio for prostate cancer. What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 57 (2003) 1101-1108
19. ASTRO. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
20. Harris E.K., and Albert A. Survivorship analysis for clinical studies (1997), Dekker, New York
21. Ray M.E., Thames H.D., Levy L.B., et al. PSA nadir predicts biochemical and distant failures after external beam radiation therapy for prostate cancer. A multi-institutional analysis. Abstract. Int J Radiat Oncol Biol Phys 60 Suppl. 1 (2004) 234
22. Feigenberg S., Hanlon H.L., Horwitz E.M., et al. Post-treatment PSA values within 6 months of 3D conformal radiotherapy for prostate cancer predict for distant metastases. Abstract. Int J Radiat Oncol Biol Phys 60 Suppl. 1 (2004) S234-S235
23. Chandra A., Levy L.B., and Kuban D.A. The predictive value of PSA nadir and time to nadir after external beam radiation for prostate cancer. Abstract. Int J Radiat Oncol Biol Phys 60 Suppl. 1 (2004) 439-440
24. Cavanaugh S.X., Kupelian P.A., Fuller C.D., et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy. Cancer 101 (2004) 96-105